ATE445405T1 - Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen - Google Patents

Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen

Info

Publication number
ATE445405T1
ATE445405T1 AT02805203T AT02805203T ATE445405T1 AT E445405 T1 ATE445405 T1 AT E445405T1 AT 02805203 T AT02805203 T AT 02805203T AT 02805203 T AT02805203 T AT 02805203T AT E445405 T1 ATE445405 T1 AT E445405T1
Authority
AT
Austria
Prior art keywords
oxidative stress
intracellular levels
glutathione
phase
compounds
Prior art date
Application number
AT02805203T
Other languages
English (en)
Inventor
Xiangqun Gao
Albena Dinkova-Kostova
Paul Talalay
Original Assignee
Brassica Foundation For Chemop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brassica Foundation For Chemop filed Critical Brassica Foundation For Chemop
Application granted granted Critical
Publication of ATE445405T1 publication Critical patent/ATE445405T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02805203T 2001-12-18 2002-12-18 Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen ATE445405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34027301P 2001-12-18 2001-12-18
PCT/US2002/040457 WO2003051313A2 (en) 2001-12-18 2002-12-18 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes

Publications (1)

Publication Number Publication Date
ATE445405T1 true ATE445405T1 (de) 2009-10-15

Family

ID=23332637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02805203T ATE445405T1 (de) 2001-12-18 2002-12-18 Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen

Country Status (9)

Country Link
US (3) US7407986B2 (de)
EP (3) EP1474158B1 (de)
JP (1) JP2005536449A (de)
CN (1) CN1620304B (de)
AT (1) ATE445405T1 (de)
AU (1) AU2002357311A1 (de)
CA (1) CA2470583C (de)
DE (1) DE60234052D1 (de)
WO (1) WO2003051313A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015913A (en) 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans
EP1474158B1 (de) * 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Vorbeugung und behandlung von oxidativer-stress-erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
MXPA06006862A (es) * 2003-12-22 2007-01-26 Alcon Inc Agentes para el tratamiento de la retinopatia diabetica y formacion de drusen en degeneracion macular.
DE602004005617T2 (de) * 2003-12-22 2007-12-13 Alcon Inc. Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
WO2006072203A1 (fr) * 2005-01-05 2006-07-13 Oliver Yoa-Pu Hu Inhibiteur ou promoteur de l’uridinediphosphate-glucuronosyltransferase2b (ugt2b)
US7744937B2 (en) * 2005-08-09 2010-06-29 Kraft Foods Global Brands Llc Chemoprotectants from crucifer seeds and sprouts
WO2008016095A1 (fr) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080311276A1 (en) * 2007-06-12 2008-12-18 Kraft Foods Holdings, Inc. Production of Glucosinolates from Agricultural By-Products & Waste
US20080311192A1 (en) * 2007-06-12 2008-12-18 Kraft Foods Holdings, Inc. Enteric-Coated Glucosinolates And Beta-Thioglucosidases
NZ589304A (en) * 2008-04-29 2012-03-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
US20090324522A1 (en) * 2008-06-18 2009-12-31 Western Holdings, Llc Skin protectant compositions
CA2729605A1 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
GB0811992D0 (en) * 2008-07-01 2008-08-06 Mithen Richard Treatment
WO2010084661A1 (ja) * 2009-01-23 2010-07-29 金印株式会社 イソチオシアネート類含有組成物、食品、食品素材、医薬品、化粧品および日用品雑貨類
EP2616061A4 (de) * 2010-09-17 2014-03-12 Brassica Prot Products Llc Formulierungen zur behandlung mit glucosinolat
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
EP2678029B1 (de) 2011-02-22 2016-11-09 Caudill Seed Company, Inc. Sprühgetrocknete myrosinase und verwendung zur herstellung von isothiocyanaten
EP2601946A1 (de) 2011-12-06 2013-06-12 Pécsi Tudomànyegyetem Behandlung und Prävention von Erkrankungen in Beziehung mit oxidativer Belastung
JP6591748B2 (ja) 2011-10-31 2019-10-16 ザ・ジョンズ・ホプキンス・ユニバーシティー 自閉症の処置のための方法および組成物
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
WO2014018874A1 (en) 2012-07-26 2014-01-30 The William M. Yarbrough Foundation Method for treating skin cancer
ITMI20121774A1 (it) * 2012-10-19 2014-04-20 Placido Bramanti Uso di un fitochimico bioattivato come agente neuroprotettivo per la prevenzione ed il trattamento di patologie correlate al sistema nervoso
CA2925546C (en) 2012-10-29 2022-06-14 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
US20150328337A1 (en) * 2012-12-19 2015-11-19 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
WO2015002279A1 (ja) * 2013-07-03 2015-01-08 味の素株式会社 グルタチオン生成促進用組成物
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
CN110198728A (zh) 2016-11-17 2019-09-03 莱诺翁股份有限公司 用谷胱甘肽组合物治疗呼吸道疾病和感染
KR20200089702A (ko) 2017-11-17 2020-07-27 레노비온, 아이엔씨. 안정한 아스코르빈산 조성물 및 그의 사용 방법
US10441578B2 (en) * 2018-01-19 2019-10-15 Louis Habash Altering expression level of glutathione S-transferase genes by treating a human subject with a nitroxide
WO2024050405A1 (en) * 2022-08-30 2024-03-07 Green Shawn J Compositions and methods for improving nitric oxide levels in intraoral, nasal and/or nasopharyngeal area

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36784A (en) 1862-10-28 Improvement in separators and smut-mach ines
US5747459A (en) 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
IT1256178B (it) * 1992-11-30 1995-11-29 Lorenzo Ferrari Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
AU7596994A (en) * 1993-11-01 1995-05-18 Free Radical Sciences, Inc. Methods and compositions for retarding the aging process
FR2723588B1 (fr) * 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
CA2650204A1 (en) * 1996-12-31 1998-07-09 Harry B. Demopoulos Pharmaceutical preparations of glutathione and methods of administration thereof
US6270780B1 (en) * 1997-07-25 2001-08-07 Chesebrough-Pond's Usa Co., Division Of Conopco Cosmetic compositions containing resveratrol
JPH11124311A (ja) * 1997-10-20 1999-05-11 Shiseido Co Ltd 光毒性抑制剤
BR9908713A (pt) * 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
CA2239205A1 (en) * 1998-05-29 1999-11-29 Gabrielle Boulianne Extension of lifespan by overexpression of a gene that increases reactive oxygen metabolism
JP3899210B2 (ja) * 1999-08-27 2007-03-28 金印株式会社 グルタチオン−ｓ−トランスフエラーゼの活性誘導物質およびこれを含む食品
EP1231886A4 (de) * 1999-11-24 2005-10-12 Access Business Group Int Llc Zusammensetzung für die hautoberfläche
AU5440901A (en) 1999-12-20 2001-07-03 Cognis France, S.A. Cosmetic and/or pharmaceutical preparations
JP2001316262A (ja) * 2000-02-29 2001-11-13 Santen Pharmaceut Co Ltd 抗酸化剤
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US6495170B1 (en) * 2000-08-16 2002-12-17 N. V. Nutricia Method of increasing the presence of glutathione in cells
KR100880498B1 (ko) 2000-08-21 2009-01-28 제드 더블유. 파헤이 이소티오시아네이트에 의한 헬리코박터의 처리
EP1474158B1 (de) * 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Vorbeugung und behandlung von oxidativer-stress-erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
AU2006242528B2 (en) * 2005-04-29 2012-09-20 Johns Hopkins University Methods of supressing UV light-induced skin carcinogenesis

Also Published As

Publication number Publication date
US8303949B2 (en) 2012-11-06
EP2138170A3 (de) 2010-06-23
EP1474158A2 (de) 2004-11-10
EP1474158A4 (de) 2006-09-13
US20130157965A1 (en) 2013-06-20
CN1620304A (zh) 2005-05-25
WO2003051313A2 (en) 2003-06-26
US20090017002A1 (en) 2009-01-15
JP2005536449A (ja) 2005-12-02
US20050063965A1 (en) 2005-03-24
AU2002357311A1 (en) 2003-06-30
CA2470583A1 (en) 2003-06-26
EP1474158B1 (de) 2009-10-14
CA2470583C (en) 2011-03-15
WO2003051313A3 (en) 2003-10-16
CN1620304B (zh) 2010-06-23
EP2138170A2 (de) 2009-12-30
US8709406B2 (en) 2014-04-29
US7407986B2 (en) 2008-08-05
EP2698153A1 (de) 2014-02-19
DE60234052D1 (de) 2009-11-26

Similar Documents

Publication Publication Date Title
ATE445405T1 (de) Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
DE59907752D1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
DE60119784D1 (de) Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60045550D1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE179888T1 (de) Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
DE60030732D1 (de) Verwendung von 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis
DE60135904D1 (de) Arzneien zur behandlung von nervenerkrankungen
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
DE69626916D1 (de) Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE428436T1 (de) Mittel zur behandlung oder prävention allergischer erkrankungen mit bearbeitetem erdnusssamen-überzug
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE602004025001D1 (de) Verbindungen zur behandlung von neuropathischen schmerzen und migräne
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties